Alex A. Adjei

38.1k total citations · 7 hit papers
476 papers, 26.2k citations indexed

About

Alex A. Adjei is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex A. Adjei has authored 476 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 283 papers in Oncology, 203 papers in Molecular Biology and 187 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex A. Adjei's work include Lung Cancer Treatments and Mutations (159 papers), Lung Cancer Research Studies (80 papers) and Colorectal Cancer Treatments and Studies (59 papers). Alex A. Adjei is often cited by papers focused on Lung Cancer Treatments and Mutations (159 papers), Lung Cancer Research Studies (80 papers) and Colorectal Cancer Treatments and Studies (59 papers). Alex A. Adjei collaborates with scholars based in United States, Canada and United Kingdom. Alex A. Adjei's co-authors include Julian R. Molina, Steven E. Schild, Ping Yang, Stephen D. Cassivi, Grace K. Dy, Irene M. Ghobrial, T. E. Witzig, Yujie Zhao, Solange Peters and Ronald S. Go and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Alex A. Adjei

461 papers receiving 25.6k citations

Hit Papers

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, T... 1999 2026 2008 2017 2008 2008 2005 2012 2001 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
    2008 2.5k citations Julian R. Molina, Steven E. Schild et al. profile →
  2. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
    2008 2.3k citations Julian R. Molina, Steven E. Schild et al. profile →
  3. Targeting Apoptosis Pathways in Cancer Therapy
    2005 1.1k citations Alex A. Adjei et al. profile →
  4. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2012 791 citations Alex A. Adjei et al. Annals of Oncology profile →
  5. Blocking Oncogenic Ras Signaling for Cancer Therapy
    2001 689 citations Alex A. Adjei profile →
  6. Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
    1999 562 citations Alex A. Adjei et al. Journal of Clinical Oncology profile →
  7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
    2015 438 citations Yujie Zhao, Alex A. Adjei profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex A. Adjei United States 78 12.9k 11.5k 8.2k 4.4k 2.5k 476 26.2k
Kwok‐Kin Wong United States 87 17.7k 1.4× 11.0k 1.0× 8.0k 1.0× 5.8k 1.3× 1.8k 0.7× 277 28.9k
Fadlo R. Khuri United States 85 14.7k 1.1× 9.9k 0.9× 5.6k 0.7× 4.5k 1.0× 1.8k 0.7× 486 27.1k
Ravi Salgia United States 90 12.5k 1.0× 10.6k 0.9× 8.4k 1.0× 3.7k 0.8× 2.4k 1.0× 626 27.5k
Giampaolo Tortora Italy 69 9.9k 0.8× 13.8k 1.2× 7.8k 1.0× 4.8k 1.1× 1.7k 0.7× 639 24.4k
William D. Figg United States 86 11.5k 0.9× 10.0k 0.9× 4.4k 0.5× 3.4k 0.8× 1.8k 0.7× 604 25.3k
Peter J. O’Dwyer United States 70 9.9k 0.8× 13.0k 1.1× 5.2k 0.6× 3.9k 0.9× 2.3k 0.9× 401 23.6k
Patricia LoRusso United States 69 10.9k 0.8× 11.2k 1.0× 4.4k 0.5× 2.8k 0.6× 2.0k 0.8× 569 21.9k
David S. Hong United States 77 9.5k 0.7× 10.4k 0.9× 6.3k 0.8× 5.8k 1.3× 2.7k 1.1× 817 23.2k
Suresh S. Ramalingam United States 74 8.8k 0.7× 15.5k 1.3× 14.5k 1.8× 4.2k 0.9× 1.5k 0.6× 593 25.5k
Mark J. Ratain United States 74 9.1k 0.7× 10.2k 0.9× 4.3k 0.5× 3.1k 0.7× 1.8k 0.7× 532 23.0k

Countries citing papers authored by Alex A. Adjei

Since Specialization
Citations

This map shows the geographic impact of Alex A. Adjei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex A. Adjei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex A. Adjei more than expected).

Fields of papers citing papers by Alex A. Adjei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex A. Adjei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex A. Adjei. The network helps show where Alex A. Adjei may publish in the future.

Co-authorship network of co-authors of Alex A. Adjei

This figure shows the co-authorship network connecting the top 25 collaborators of Alex A. Adjei. A scholar is included among the top collaborators of Alex A. Adjei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex A. Adjei. Alex A. Adjei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schram, Alison M., Alex A. Adjei, Anthony J. Olszanski, et al.. (2025). A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors. ESMO Open. 10(3). 104300–104300.
2.
Adjei, Alex A., Kwok‐Kin Wong, María Koehler, et al.. (2024). IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3186–TPS3186. 3 indexed citations
3.
Smith, Cambray, Jan C. Buckner, Alex A. Adjei, et al.. (2021). Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center. PLoS ONE. 16(12). e0261478–e0261478. 4 indexed citations
4.
Adjei, Alex A., Sai‐Hong Ignatius Ou, Cheryl Ho, et al.. (2021). Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships. Journal of Thoracic Oncology. 16(5). 706–708.
5.
Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations
6.
Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376. 16 indexed citations
7.
Amaravadi, Ravi K., Russell J. Schilder, Lainie P. Martin, et al.. (2015). A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics. 14(11). 2569–2575. 101 indexed citations
8.
Molina, Julian R., Nathan R. Foster, Thanyanan Reungwetwattana, et al.. (2014). A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer. 85(2). 245–250. 37 indexed citations
9.
Zhao, Yujie & Alex A. Adjei. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology. 11(7). 385–400. 297 indexed citations
10.
Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations
11.
Wee, Wen, Wells A. Messersmith, Grace K. Dy, et al.. (2012). Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research. 18(7). 2048–2055. 42 indexed citations
12.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782. 74 indexed citations
13.
An, Ming-Wen, Sumithra J. Mandrekar, Megan E. Branda, et al.. (2011). Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials. Clinical Cancer Research. 17(20). 6592–6599. 22 indexed citations
14.
15.
Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations
16.
Leil, Tarek A., Chiaki Endo, Araba A. Adjei, et al.. (2007). Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene. Cancer Research. 67(18). 8772–8782. 30 indexed citations
17.
Erlichman, Charles, Manuel Hidalgo, Joseph Boni, et al.. (2006). Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 24(15). 2252–2260. 109 indexed citations
18.
Cynthia, X., Araba A. Adjei, Oreste E. Salavaggione, et al.. (2005). Human Aromatase: Gene Resequencing and Functional Genomics. Cancer Research. 65(23). 11071–11082. 155 indexed citations
19.
Jatoi, Aminah, Shauna L. Hillman, Philip J. Stella, et al.. (2005). Should Elderly Non–Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. Journal of Clinical Oncology. 23(36). 9113–9119. 100 indexed citations
20.
Goldberg, Richard M., Scott H. Kaufmann, Pamela J. Atherton, et al.. (2002). A phase I study of sequential irinotecan and5-fluorouracil/leucovorin. Annals of Oncology. 13(10). 1674–1680. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kwok‐Kin Wong Breakdown of academic impact, for papers by Fadlo R. Khuri Breakdown of academic impact, for papers by Ravi Salgia Breakdown of academic impact, for papers by Giampaolo Tortora Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Peter J. O’Dwyer Breakdown of academic impact, for papers by Patricia LoRusso Breakdown of academic impact, for papers by David S. Hong Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Mark J. Ratain
Rankless by CCL
2026